HK1147192A1 - Extended release formulation containing a wax - Google Patents
Extended release formulation containing a waxInfo
- Publication number
- HK1147192A1 HK1147192A1 HK11101196.7A HK11101196A HK1147192A1 HK 1147192 A1 HK1147192 A1 HK 1147192A1 HK 11101196 A HK11101196 A HK 11101196A HK 1147192 A1 HK1147192 A1 HK 1147192A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- wax
- release formulation
- extended release
- formulation containing
- extended
- Prior art date
Links
- 238000013265 extended release Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7033208P | 2008-03-21 | 2008-03-21 | |
| PCT/US2009/001744 WO2009117130A2 (en) | 2008-03-21 | 2009-03-18 | Extended release forumulation containing a wax |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1147192A1 true HK1147192A1 (en) | 2011-08-05 |
Family
ID=41051034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11101196.7A HK1147192A1 (en) | 2008-03-21 | 2011-02-08 | Extended release formulation containing a wax |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090238873A1 (es) |
| EP (2) | EP2276465B1 (es) |
| JP (1) | JP2011515400A (es) |
| KR (1) | KR101609279B1 (es) |
| CN (2) | CN102036656A (es) |
| AU (1) | AU2009226091B2 (es) |
| BR (1) | BRPI0908596A2 (es) |
| CA (1) | CA2718697C (es) |
| ES (1) | ES2525005T3 (es) |
| HK (1) | HK1147192A1 (es) |
| MX (1) | MX2010010280A (es) |
| NZ (2) | NZ588695A (es) |
| WO (1) | WO2009117130A2 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2638240C (en) * | 2008-08-29 | 2010-02-02 | Alexander Macgregor | Method of treating dysglycemia and glucose excursions |
| US20130209553A1 (en) | 2010-04-15 | 2013-08-15 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of pramipexole |
| CN102247313A (zh) * | 2010-06-11 | 2011-11-23 | 北京润德康医药技术有限公司 | 一种以莫西沙星为活性成分的口服缓释固体制剂 |
| WO2011161504A1 (en) * | 2010-06-23 | 2011-12-29 | Micro Labs Limited | Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof |
| CN101982166A (zh) * | 2010-10-27 | 2011-03-02 | 北京华禧联合科技发展有限公司 | 莫西沙星的缓释剂型及其制备方法 |
| CN102119912A (zh) * | 2011-01-25 | 2011-07-13 | 南京白敬宇制药有限责任公司 | 一种非水溶性药物缓释制剂的制备方法 |
| US20120270860A1 (en) | 2011-04-19 | 2012-10-25 | Gihyun Yoon | Methods for treating or preventing alcohol-related disorders or craving-related disorders |
| US10702485B2 (en) | 2011-07-09 | 2020-07-07 | Syntrix Biosystems Inc. | Compositions and methods for overcoming resistance to tramadol |
| GB201118182D0 (en) * | 2011-10-21 | 2011-12-07 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2013090452A1 (en) * | 2011-12-12 | 2013-06-20 | Orbis Biosciences, Inc. | Sustained release particle formulations |
| WO2013124768A1 (en) * | 2012-02-20 | 2013-08-29 | Lupin Limited | Bilayer tablet of dronedarone |
| DE102012102414A1 (de) * | 2012-03-21 | 2013-10-10 | Michael Dittgen | Pharmazeutische Zusammensetzung für die einmal tägliche Anwendung antidiabetischer Arzneimittel wie Metformin mit Zwei-Puls-Freisetzung |
| PL2872121T3 (pl) | 2012-07-12 | 2019-02-28 | SpecGx LLC | Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania |
| DE102013009114A1 (de) | 2013-05-29 | 2014-12-04 | Franz Gerstheimer | Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen |
| KR101597004B1 (ko) | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
| US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| CN103690506B (zh) * | 2013-11-08 | 2015-05-13 | 舒泰神（北京）生物制药股份有限公司 | 一种曲司氯铵缓释组合物及其制备方法 |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| KR20210154264A (ko) * | 2016-05-03 | 2021-12-20 | 스펙트릭스 테라퓨틱스, 엘엘씨 | 갑상샘 호르몬 또는 이의 유사체를 제공하는 조성물 및 방법 |
| CN106420738B (zh) * | 2016-10-14 | 2018-02-09 | 杨彦玲 | 一种左旋氨氯地平或其盐的缓释制剂及其制备方法 |
| WO2019183470A2 (en) | 2018-03-22 | 2019-09-26 | Incarda Therapeutics, Inc. | A novel method to slow ventricular rate |
| KR20200070539A (ko) | 2018-12-10 | 2020-06-18 | 신성대학교 산학협력단 | 유효성분을 함유하는 왁스 파티클 및 이의 제조방법 |
| US11000488B2 (en) | 2019-03-22 | 2021-05-11 | Syntrix Biosystems Inc. | Treating pain using desmetramadol |
| CN110464710A (zh) * | 2019-09-02 | 2019-11-19 | 新华制药（高密）有限公司 | 一种盐酸地尔硫*片及其制备方法 |
| KR102530612B1 (ko) | 2020-08-21 | 2023-05-09 | 한국휴텍스제약 주식회사 | 자가과립화 기법을 이용한 딜티아젬 서방정 조성물의 제조방법 |
| CN114805947B (zh) * | 2022-04-26 | 2023-04-11 | 四川大学 | 一种超疏水抗菌复合膜及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2951729A (en) * | 1944-03-23 | 1960-09-06 | Charles W Skarstrom | Gas bearing |
| US2951792A (en) * | 1959-11-18 | 1960-09-06 | Smith Kline French Lab | Sustained release pharmaceutical tablets |
| JP3962108B2 (ja) * | 1995-04-03 | 2007-08-22 | 中外製薬株式会社 | スクラルファート含有製剤組成物 |
| CA2217233A1 (en) * | 1995-04-03 | 1996-10-10 | Chugai Seiyaku Kabushiki Kaisha | Sucralfate containing pharmaceutical composition |
| CZ295461B6 (cs) * | 1997-08-26 | 2005-08-17 | Aventis Pharmaceuticals Inc. | Farmaceutický prostředek ve formě dvouvrstvé tablety |
| JPH11209306A (ja) * | 1998-01-20 | 1999-08-03 | Nichiko Pharmaceutical Co Ltd | 高薬物含有率徐放製剤の製法 |
| DE10031043A1 (de) * | 2000-06-26 | 2002-02-14 | Bayer Ag | Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung |
| WO2002100438A1 (en) * | 2001-06-12 | 2002-12-19 | Blue Cross Laboratories Limited | Oral controlled release drug delivery system with husk powder from lepidium sativum seeds |
| US7157100B2 (en) * | 2002-06-04 | 2007-01-02 | J.B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical composition for controlled drug delivery system |
| US9060941B2 (en) * | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US20050220877A1 (en) * | 2004-03-31 | 2005-10-06 | Patel Ashish A | Bilayer tablet comprising an antihistamine and a decongestant |
| MX2007013327A (es) * | 2005-04-25 | 2008-04-21 | Teva Pharma | Formulaciones de liberacion prolongada. |
| US20070178155A1 (en) * | 2006-01-31 | 2007-08-02 | Jiang David Yihai | Preparation for gastric buoyant sustained drug release dosage form |
| AU2007272951A1 (en) * | 2006-07-11 | 2008-01-17 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations |
| US8765178B2 (en) * | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
-
2009
- 2009-03-18 NZ NZ588695A patent/NZ588695A/xx not_active IP Right Cessation
- 2009-03-18 CN CN2009801182220A patent/CN102036656A/zh active Pending
- 2009-03-18 BR BRPI0908596A patent/BRPI0908596A2/pt not_active IP Right Cessation
- 2009-03-18 EP EP09722765.6A patent/EP2276465B1/en not_active Not-in-force
- 2009-03-18 JP JP2011500811A patent/JP2011515400A/ja active Pending
- 2009-03-18 US US12/406,272 patent/US20090238873A1/en not_active Abandoned
- 2009-03-18 KR KR1020107023462A patent/KR101609279B1/ko active IP Right Grant
- 2009-03-18 WO PCT/US2009/001744 patent/WO2009117130A2/en active Application Filing
- 2009-03-18 CA CA2718697A patent/CA2718697C/en active Active
- 2009-03-18 ES ES09722765.6T patent/ES2525005T3/es active Active
- 2009-03-18 MX MX2010010280A patent/MX2010010280A/es active IP Right Grant
- 2009-03-18 AU AU2009226091A patent/AU2009226091B2/en not_active Ceased
- 2009-03-18 CN CN201510337180.7A patent/CN104922683A/zh active Pending
- 2009-03-18 EP EP11169586A patent/EP2366380A1/en not_active Withdrawn
- 2009-03-18 NZ NZ602968A patent/NZ602968A/en not_active IP Right Cessation
-
2011
- 2011-02-08 HK HK11101196.7A patent/HK1147192A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009226091B2 (en) | 2014-07-10 |
| MX2010010280A (es) | 2010-12-15 |
| CA2718697C (en) | 2014-09-23 |
| KR101609279B1 (ko) | 2016-04-05 |
| CA2718697A1 (en) | 2009-09-24 |
| BRPI0908596A2 (pt) | 2015-09-15 |
| KR20100129776A (ko) | 2010-12-09 |
| WO2009117130A3 (en) | 2010-01-28 |
| WO2009117130A2 (en) | 2009-09-24 |
| AU2009226091A1 (en) | 2009-09-24 |
| EP2276465A2 (en) | 2011-01-26 |
| NZ588695A (en) | 2012-11-30 |
| NZ602968A (en) | 2014-04-30 |
| CN102036656A (zh) | 2011-04-27 |
| CN104922683A (zh) | 2015-09-23 |
| EP2276465B1 (en) | 2014-10-22 |
| ES2525005T3 (es) | 2014-12-16 |
| EP2366380A1 (en) | 2011-09-21 |
| JP2011515400A (ja) | 2011-05-19 |
| US20090238873A1 (en) | 2009-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1147192A1 (en) | Extended release formulation containing a wax | |
| ZA201004793B (en) | Capsule formulation | |
| IL217153A0 (en) | Controlled release formulations | |
| EP2296681A4 (en) | HOMOEOPATHIC FORMULATION | |
| EP2315816A4 (en) | CUTTING MATERIALS | |
| GB0815435D0 (en) | Formulations | |
| GB2459691B (en) | Formulations | |
| GB0823269D0 (en) | Formulations | |
| IL206467A0 (en) | Formulation | |
| IL212447A (en) | Composition with extended release containing 2-oxo-1-pyrrolidine sequels | |
| ZA201102446B (en) | Oral formulation | |
| GB0821789D0 (en) | Formulations | |
| EP2296709A4 (en) | NIACIN FORMULATIONS WITH MODIFIED RELEASE | |
| EP2251719A4 (en) | PEEL FILM | |
| GB0822633D0 (en) | Formulation | |
| EP2307021A4 (en) | FORMULATIONS | |
| IL209462A0 (en) | Opiorphin for use as a psychotimulant agent | |
| ZA201004772B (en) | Novel formulation | |
| IL212271A (en) | Elongated release vehicles containing 2-oxo-1-pyrrolidine | |
| GB0715723D0 (en) | Formulation | |
| GB0814376D0 (en) | Formulation | |
| GB0712972D0 (en) | Formulation | |
| GB0921378D0 (en) | Formulations | |
| GB0916030D0 (en) | Formulations | |
| GB0822171D0 (en) | Temisartan formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220316 |